Report of Twelve Years Experience in Open Study of Skinner Herpes Simplex Vaccine Towards Prevention of Herpes Genitalis

Overview

Journal Med Microbiol Immunol

Specialty Allergy & Immunology

Date 1992 Jan 1

PMID 1549071

Citations 5

Authors

G R Skinner

C Fink

J Melling

C Wiblin

B Thornton

J Hallworth

W Gardner

P McLeish

C Hartley

A Buchan

Affiliations

Soon will be listed here.

Abstract

Three hundred and forty-seven subjects at risk for herpes genitalis were vaccinated with Skinner vaccine, NFUAc.HSV1.(S-MRC5), and were followed for an average duration of 2 years representing a total consortship of 664.4 years. Based on survey information obtained during this consortship, there were estimated to be 3076 recurrences which summated to 3.5 years total duration of disease and comprised at least 6794 lesions; there were an estimated 51997 episodes of intercourse including at least 241 episodes of unprotected intercourse in the presence of herpetic lesions. The rate of contraction of herpes genitalis was 6 of 54 consorts (11.1%) who received one vaccination and 7 of 293 (2.4%) who received two, three of four vaccinations. There was no evidence of physical or psychological side effects from vaccination.

Citing Articles

Towards an effective genital herpes vaccine: past lessons and future prospects.

Halford W Future Virol. 2013; 2(1):1-6.

PMID: 23843891 PMC: 3704169. DOI: 10.2217/17460794.2.1.1.

Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.

Halford W, Geltz J, Gershburg E PLoS One. 2013; 8(6):e65523.

PMID: 23755244 PMC: 3675040. DOI: 10.1371/journal.pone.0065523.

Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Ferenczy M Curr Pharm Des. 2007; 13(19):1975-88.

PMID: 17627531 PMC: 3839066. DOI: 10.2174/138161207781039779.

Control of STDs--the role of prophylactic vaccines against herpes simplex virus.

Stanberry L Sex Transm Infect. 1999; 74(6):391-4.

PMID: 10195045 PMC: 1758161. DOI: 10.1136/sti.74.6.391.

Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.

Davies J, Hallworth J, McLeish P, Randall S, Martin B, Buchan A Med Microbiol Immunol. 1994; 183(2):105-17.

PMID: 7935160 DOI: 10.1007/BF00277161.

References

Klein R, Moser H, Moucha R, Hilfenhaus J . Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice. Arch Virol. 1981; 68(2):73-80. DOI: 10.1007/BF01314437. View

Skinner G, Woodman C, Hartley C, Buchan A, Fuller A, Durham J . Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis. Br J Vener Dis. 1982; 58(6):381-6. PMC: 1046107. DOI: 10.1136/sti.58.6.381. View

Mertz G, Ashley R, Burke R, Benedetti J, Critchlow C, Jones C . Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis. 1990; 161(4):653-60. DOI: 10.1093/infdis/161.4.653. View

Skinner G, Williams D, Moles A, Sargent A . Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus. Arch Virol. 1980; 64(4):329-38. PMC: 7101888. DOI: 10.1007/BF01320618. View

Lee F, Pereira L, Griffin C, Reid E, Nahmias A . A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies. J Virol Methods. 1986; 14(2):111-8. DOI: 10.1016/0166-0934(86)90041-8. View

Blacklaws B, Krishna S, Minson A, Nash A . Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants. Virology. 1990; 177(2):727-36. DOI: 10.1016/0042-6822(90)90539-4. View

Kitces E, Morahan P, Tew J, Murray B . Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine. Infect Immun. 1977; 16(3):955-60. PMC: 421057. DOI: 10.1128/iai.16.3.955-960.1977. View

Carter C, Hartley C, Skinner G, Turner S, Easty D . Experimental ulcerative herpetic keratitis. IV. Preliminary observations on the efficacy of a herpes simplex subunit vaccine. Br J Ophthalmol. 1981; 65(10):679-82. PMC: 1039636. DOI: 10.1136/bjo.65.10.679. View

Skinner G . Nice work for everybody except the patient. Vaccine. 1989; 7(5):382-4. DOI: 10.1016/0264-410x(89)90149-7. View

10.

Holmes P, Hallworth J, Stocker D, Skinner G . Augmentation of the neutralisation test for type 1 HSV: evidence of high representation of neutralising antibody in the adult community. Med Microbiol Immunol. 1985; 174(4):167-75. DOI: 10.1007/BF02123693. View

11.

Cappel R, Sprecher S, de Cuyper F, De Braekeleer J . Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol. 1985; 16(2):137-45. DOI: 10.1002/jmv.1890160206. View

12.

Cappel R, Sprecher S, Rickaert F, de Cuyper F . Immune response to a DNA free herpes simplex vaccine in man. Arch Virol. 1982; 73(1):61-7. DOI: 10.1007/BF01341728. View

13.

Chan W . Protective immunization of mice with specific HSV-1 glycoproteins. Immunology. 1983; 49(2):343-52. PMC: 1454196. View

14.

Skinner G, Fink C, Cowan M, Buchan A, Fuller A, Hartley C . Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med Microbiol Immunol. 1987; 176(3):161-8. DOI: 10.1007/BF00193897. View

15.

Lee F, Coleman R, Pereira L, Bailey P, Tatsuno M, Nahmias A . Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol. 1985; 22(4):641-4. PMC: 268483. DOI: 10.1128/jcm.22.4.641-644.1985. View

16.

Muniu E, Durham J, Shariff D, Hartley C, Fuller A, Melling J . Antibody reactivity with Skinner HSV vaccine. Med Microbiol Immunol. 1987; 176(6):315-27. DOI: 10.1007/BF00194891. View

17.

Woodman C, Stocker D, Sugrue D, Desberbasques M, Hartley C, Fuller A . The relative infrequency and low levels of neutralising and immunoprecipitating antibody to herpes simplex viruses types 1 and 2 in patients with a history of recurrent herpes genitalis. Med Microbiol Immunol. 1983; 171(4):243-50. DOI: 10.1007/BF02123498. View

18.

Heine J, Honess R, Cassai E, Roizman B . Proteins specified by herpes simplex virus. XII. The virion polypeptides of type 1 strains. J Virol. 1974; 14(3):640-51. PMC: 355559. DOI: 10.1128/JVI.14.3.640-651.1974. View

19.

Watson D, Wildy P . The preparation of 'monoprecipitin' antisera to herpes virus specific antigens. J Gen Virol. 1969; 4(2):163-8. DOI: 10.1099/0022-1317-4-2-163. View

20.

Skinner G, Williams D, Buchan A, Whitney J, Harding M, Bodfish K . Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection. Med Microbiol Immunol. 1978; 166(1-4):119-32. DOI: 10.1007/BF02121141. View